Jiangsu Asieris Pharmaceutical Technology Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2010)

Organization Overview

First Clinical Trial
2018
NCT03672240
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Asieris Pharmaceuticals (AUS) Pty Ltd. | Asieris Pharmaceutical Technologies Co., Ltd. | Jiangsu Yahong Meditech Co.,Ltd. | Jiangsu Yahong Meditech Co., Ltd aka Asieris

Active Ingredients

Drugs in Phase 3 Trials (3)

apl-1202 (5 trials)

epirubicin (ellence) (1 trial)

hexyl 5-aminolevulinate (Cysview) (1 trial)

Drugs in Phase 2 Trials (1)

tislelizumab (1 trial)

Drugs in Phase 1 Trials (2)

apl-1501 (2 trials)

nepicastat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6